BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 12684393)

  • 21. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer.
    Kurebayashi J; Otsuki T; Kunisue H; Tanaka K; Yamamoto S; Sonoo H
    Clin Cancer Res; 2000 Feb; 6(2):512-8. PubMed ID: 10690532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct mRNA, protein expression patterns and distribution of oestrogen receptors alpha and beta in human primary breast cancer: correlation with proliferation marker Ki-67 and clinicopathological factors.
    Jarzabek K; Koda M; Kozlowski L; Mittre H; Sulkowski S; Kottler ML; Wolczynski S
    Eur J Cancer; 2005 Dec; 41(18):2924-34. PubMed ID: 16289616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.
    Haugan Moi LL; Hauglid Flågeng M; Gandini S; Guerrieri-Gonzaga A; Bonanni B; Lazzeroni M; Gjerde J; Lien EA; DeCensi A; Mellgren G
    Clin Cancer Res; 2010 Apr; 16(7):2176-86. PubMed ID: 20332317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer.
    Esslimani-Sahla M; Simony-Lafontaine J; Kramar A; Lavaill R; Mollevi C; Warner M; Gustafsson JA; Rochefort H
    Clin Cancer Res; 2004 Sep; 10(17):5769-76. PubMed ID: 15355905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nuclear corepressor 1 expression predicts response to first-line endocrine therapy for breast cancer patients on relapse.
    Zhang ZH; Yamashita H; Toyama T; Yamamoto Y; Kawasoe T; Ibusuki M; Tomita S; Sugiura H; Kobayashi S; Fujii Y; Iwase H
    Chin Med J (Engl); 2009 Aug; 122(15):1764-8. PubMed ID: 19781322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.
    Girault I; Bièche I; Lidereau R
    Maturitas; 2006 Jul; 54(4):342-51. PubMed ID: 16822624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas.
    Girault I; Tozlu S; Lidereau R; Bièche I
    Clin Cancer Res; 2003 Oct; 9(12):4415-22. PubMed ID: 14555514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay.
    Bièche I; Noguès C; Paradis V; Olivi M; Bedossa P; Lidereau R; Vidaud M
    Clin Cancer Res; 2000 Feb; 6(2):452-9. PubMed ID: 10690523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer.
    Iwase H; Zhang Z; Omoto Y; Sugiura H; Yamashita H; Toyama T; Iwata H; Kobayashi S
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S34-8. PubMed ID: 12819932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
    Bostner J; Ahnström Waltersson M; Fornander T; Skoog L; Nordenskjöld B; Stål O
    Oncogene; 2007 Oct; 26(49):6997-7005. PubMed ID: 17486065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time.
    Span PN; Waanders E; Manders P; Heuvel JJ; Foekens JA; Watson MA; Beex LV; Sweep FC
    J Clin Oncol; 2004 Feb; 22(4):691-8. PubMed ID: 14966093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
    Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
    Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM
    Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
    Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
    Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer.
    Zhang Z; Yamashita H; Toyama T; Yamamoto Y; Kawasoe T; Iwase H
    Clin Cancer Res; 2006 Nov; 12(21):6410-4. PubMed ID: 17085653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.